Rating Change
Canaccord Genuity analysts initiated coverage on Maze Therapeutics, Inc. (NASDAQ:MAZE) with a rating of Buy on October 19, 2026.
new coverageNASDAQ:MAZE
Canaccord Genuity Initiates Coverage on Maze Therapeutics, Inc. (MAZE) with Buy
Canaccord Genuity analysts initiated coverage on Maze Therapeutics, Inc. (NASDAQ:MAZE) with a rating of Buy on October 19, 2026.
At publication ·
What changed
Maze Therapeutics, Inc. (NASDAQ:MAZE) · new coverage
- Firm
- Canaccord Genuity
- Rating
- Buy
- Price at event
- $29.70
- Market capitalization
- $1.9B
At a glance
Key takeaways
- Canaccord Genuity initiated Buy coverage on Maze Therapeutics (NASDAQ:MAZE) on October 19, 2026.
- MAZE trades at $29.70 with a $1.9B market capitalization and gained 4.4% over the past 52 weeks.
Market Context
Maze Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $29.70 with a market capitalization of $1.9B. The stock has gained 4.4% over the past 52 weeks.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Maze Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Maze Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 19, 2026 | Canaccord Genuity | Buy | N/A |
| Sep 24, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 23, 2026 | Citigroup | Buy | N/A |
| Sep 23, 2026 | Wedbush | Outperform | N/A |
| Sep 22, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View MAZE Stock Page
Frequently Asked Questions
What does the Buy rating mean for MAZE?
A rating of Buy from Canaccord Genuity reflects the analyst's outlook on Maze Therapeutics, Inc. (NASDAQ:MAZE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MAZE forecast page.